Maternal Multivitamin Use Tied to Lower Risk of Child ASD

Share this content:
Maternal Multivitamin Use Tied to Lower Risk of Child ASD
Maternal Multivitamin Use Tied to Lower Risk of Child ASD

THURSDAY, Oct. 5, 2017 (HealthDay News) -- Multivitamin supplementation during pregnancy is tied to a reduced risk of autism spectrum disorder (ASD) with intellectual disability, according to a study published online Oct. 4 in BMJ.

Elizabeth A. DeVilbiss, Ph.D., from Drexel University in Philadelphia, and colleagues performed an observational prospective cohort study in which they used population registries to identify 273,107 mother-child pairs with children born between 1996 and 2007.

The researchers found that the prevalence of ASD with intellectual disability was 0.26 percent in the maternal multivitamin use group and 0.48 percent in the no nutritional supplementation use group. Lower odds of ASD with intellectual disability were seen in the maternal multivitamin use group with or without additional iron or folic acid or both compared with mothers who did not use multivitamins, iron, and folic acid (odds ratio 0.69; 95 percent confidence interval, 0.57 to 0.84). In propensity score matched (odds ratio, 0.68; 95 percent confidence interval, 0.54 to 0.86) and sibling control matched (odds ratio, 0.77; 95 percent confidence interval, 0.52 to 1.15) analyses, similar results were seen.

"Further scrutiny of maternal nutrition and its role in the cause of autism is recommended," conclude the authors.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Doctors Urged to Speak With Patients About Firearms

Doctors Urged to Speak With Patients About Firearms

Making a public commitment is encouraged as a positive action that physicians can take

Machine Learning Model Predicts Risk of Upgrade to Breast CA

Machine Learning Model Predicts Risk of Upgrade to ...

Model can predict risk of upgrade of high-risk breast lesions to cancer using traditional, text features

Glycemic Control Up With Oral Semaglutide in Type 2 Diabetes

Glycemic Control Up With Oral Semaglutide in Type ...

Phase 3 studies next to assess longer-term/clinical outcomes, safety

is free, fast, and customized just for you!

Already a member?

Sign In Now »